Unicycive Therapeutics/$UNCY
13:30
15:10
16:45
18:25
20:00
1D1W1MYTD1Y5YMAX
About Unicycive Therapeutics
Unicycive Therapeutics Inc is a clinical-stage biotechnology company focused on identifying, developing, and commercializing therapies to address unmet medical needs, with a primary focus on kidney disease. The company is advancing two key product candidates: oxylanthanum carbonate (OLC), a phosphate binder for the treatment of hyperphosphatemia in chronic kidney disease patients on dialysis, and UNI-494, a drug candidate for the treatment of acute kidney injury.
Ticker
$UNCY
Sector
Primary listing
Employees
22
Headquarters
Website
UNCY Metrics
BasicAdvanced
$137m
-
-$2.11
1.73
-
Price and volume
Market cap
$137m
Beta
1.73
52-week high
$8.74
52-week low
$3.71
Average daily volume
2.3m
Financial strength
Current ratio
2.399
Quick ratio
2.061
Long term debt to equity
0.576
Total debt to equity
2.162
Interest coverage (TTM)
-535.09%
Profitability
EBITDA (TTM)
-29.931
Management effectiveness
Return on assets (TTM)
-40.56%
Return on equity (TTM)
-163.14%
Valuation
Price to book
3.35
Price to tangible book (TTM)
3.35
Price to free cash flow (TTM)
-3.31
Free cash flow yield (TTM)
-30.21%
Free cash flow per share (TTM)
-1.514
Growth
Earnings per share change (TTM)
-59.61%
3-year earnings per share growth (CAGR)
-52.28%
UNCY News
AllArticlesVideos
UNCY INVESTOR ALERT: Kirby McInerney LLP Investigates Potential Claims Involving Unicycive Therapeutics, Inc.
Business Wire·3 weeks ago
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged To Contact Glancy Prongay Wolke & Rotter LLP, a Leading Securities Fraud Law Firm
Business Wire·3 weeks ago
Securities Fraud Investigation Into Unicycive Therapeutics, Inc. (UNCY) Announced – Shareholders Who Lost Money Urged to Contact The Law Offices of Frank R. Cruz
Business Wire·4 weeks ago
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.